相关实验视频

Updated: Jun 6, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

具有偏差IL-2的高亲和度全人类抗EpCAM抗体表现出强大的抗瘤活性

Zhi Wang¹, Mingkai Wang¹, Quanxiao Li¹

¹MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.

|November 27, 2024

概括

研究人员通过将抗EpCAM抗体与IL-2变体融合而开发了一种新的免疫细胞因子治疗方法. 这种融合,m801.2,表现出增强的抗瘤活性和T细胞激活,为癌症治疗提供了一个有前途的新策略.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

单克隆抗体 (mAbs) 在癌症治疗中至关重要,但与固体瘤疗效作斗争.
将细胞因子与瘤向的mAbs融合,可以通过激活局部免疫细胞来增强抗瘤活性.
抗体-细胞因子融合格式的最佳设计和有效性需要进一步研究.

研究的目的:

确定和描述一种新的抗体-细胞因子融合,用于增强癌症免疫治疗.
为了评估与IL-2变种融合的抗EpCAM抗体的治疗潜力.

主要方法:

确定了一个完全人类的mAb (m801) 针对EpCAM.
m801与IL-2变种 (IL-2v) 融合成两个配置:m801.2和m801.3.3.
评估了生物物理特性,EpCAM结合,IL-2受体结合和T细胞激活.
在SW480异种移植小鼠模型中评估了治疗疗效.

主要成果:

与m801.3.3相比,m801.2表现出优越的生物物理特性 (稳定性,均性,低聚合性).
m801.2 显示出强大的EpCAM结合亲和力 (KD = 0.6 nM) 和IL-2受体β (IL-2Rβ) 偏差结合 (KD = 27.3 nM).
m801.2显著增强T细胞激活和抑制瘤生长体内具有良好的耐受性.

结论:

m801.2免疫细胞因子代表了对表达EpCAM的癌症的有前途的治疗候选者.
这项研究为设计有效的抗体-细胞因子融合疗法提供了有价值的框架.
瘤微环境中的向免疫细胞激活对于增强抗瘤疗效至关重要.

关键词:

在 EpCAM 中使用 EpCAM.这是一种抗瘤药物.有偏见的IL-2变种.完全人类的抗体.免疫细胞因子的免疫细胞因子.

更多相关视频

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.